Research on the Joint Reformation for Public Health Services, Medical Insurance and Medical Production Circulation from the Perspective of System Science

Abstract

Objective To study the linkage points in the reform of public health services, medical insurance and medical production circulation and provide countermeasures for optimizing the reform. Methods The theory of system science was used to analyze the new emergent property of key linkage points in the main reform departments. Results and Conclusion The research found that four linkage points were not active, and all departments of the reform should strengthen their linkage in the following aspects. The departmental linkage in the decision-making mechanism should be strengthened, which requires to revise the assessment indicators of essential drugs in time, and carry out relevant policies. Besides, the linkage of various departments to supervise the use of medical insurance fund should be strengthened. Therefore, the National Health Commission (NHC) and National Medical Products Administration (NMPA) should play their supervisory roles. Lastly, the construction of adverse reaction data sharing platform should be improved.

Keywords

linkage reform / management / linkage point / countermeasure

References

[1] Ministry of Human Resources and Social Security. Guidance of the Ministry of Human Resources and Social Security on Actively Promoting the Joint Reform of Medical Care, Medical Insurance and Medicine[J]. Shandong Human Resources and Social Security, 2016 (8): 61-62.

[2] Hu Zhimin, Liu Xiaoxi, Xie Yu. Textual quantitative analysis of healthcare reform policies on role of joint reform of medical service, medication and medical insurance in past ten years from perspective of policy tools[J]. China Medical Herald, 2018, 15 (33): 166-171.

[3] Jia Qiong, Wu Haibo, Xu Feng. Quantitative analysis of medical-insurance-medicine linkage in China based on policy tools[J]. Chinese Health Service Management, 2021, 38 (1): 34-37+49.

[4] Zhou Qian. Analysis and thinking of drug procurement policy - based on the perspective of the linkage of medical care, medical insurance and medicine[J]. China Health Insurance, 2020 (8): 22-25.

[5] Zhou Yan, Fang Pengqian. Discussion on the supervision and constraint mechanism of medical behavior of medical staff under the background of “tripartite system reform”[J]. Chinese Hospital Management, 2018, 38 (11): 7-9.

[6] Qian Xuesen. Systems Engineering Theory[M]. Shanghai: Shanghai Jiao Tong University Press, 2007: 162.

[7] Miao Dongsheng. Essentials of Systems Science[M]. Beijing: Renmin University of China Press, 2016: 20-31.

[8] Sun Lihua. Drug management should shift to mission management[N]. Health News, 2010-04-13 (005).

[9] National Healthcare Security Administration. Guidelines on Establishing and Improving the “Dual Channel” Management Mechanism for Drugs Negotiated by National Medical Insurance[EB/OL]. (2021-04-22)[2022-04-25]. http://www.gov.cn/zhengce/zhengceku/2021-05/10/content_5605595.htm.

[10] National Healthcare Security Administration. A teleconference on the 2022 national campaign to crack down on fraud and insurance fraud was held in Beijing[EB/OL]. (2022-04-01)[2022-04-25]. http://www.nhsa.gov.cn/art/2022/4/1/art_14_8047.html.

[11] National Healthcare Security Administration. Announcement on the Special Flight Inspection of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology[EB/OL]. (2022-04-20)[2022-04-25]. http://www.nhsa.gov.cn/art/2022/4/20/art_14_8122.html.

[12] National Healthcare Security Administration. Typical cases exposed by the National Healthcare Security Administration in the first phase of 2022 (24 cases)[EB/OL]. (2022-02-27)[2022-04-25]. http://www.nhsa.gov.cn/art/2022/2/27/art_74_7848.html.

[13] Liu Changrong. Why can’t I buy medicines with medical insurance in the hospital?[J]. Elderly Chinese, 2021 (13): 7.

[14] National Health Commission of the People’s Republic of China. Notice on the Preparation and Use of Selected Drugs for Centralized Drug Procurement by the State[EB/OL]. (2019-01-25)[2022-04-25]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=628ac5004d244af7ad53c0b109f0c2df.

[15] National Health Commission of the People’s Republic of China. Circular on the Issuance of Opinions on Strengthening Pharmaceutical Management in Medical Institutions to Promote Rational Drug Use[EB/OL].(2020-02-26)[2022-04-25]. http://www.nhc.gov.cn/yzygj/s7659/202002/ea3b96d1ac094c47a1fc39cf00f3960e.shtm.

[16] Yang Shuo, Li Yu, Hu Jian. Analysis on the relevant indicators of the policy on the retention and use of the balance of the centralized procurement of medicines[J]. China Health Insurance, 2022 (3): 68-70.

[17] General Office of the State Council. Opinions on Improving the National Essential Medicine System[EB/OL]. (2018-09-19)[2022-04-25]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=feb1852027a949f7894b03394784dd3f.

[18] National Health Commission of the People’s Republic of China. Notice on Further Strengthening the Management of the Allocation and Use of Essential Drugs in Public Medical Institutions[EB/OL]. (2019-01-07)[2022-04-25]. http://www.nhc.gov.cn/cms-s earch/xxgk/getManuscriptXxgk.htm?id=b3f6fb3f55314a7faff97386908bd4f4.